Gimv’s portfolio companies delivered robust results in the first quarter of 2026, with both revenue and profitability rising compared to the same period last year.
Supported by sustained growth momentum and final FY2025 results that met or slightly exceeded expectations, the portfolio achieved a positive return of 3.9 percent (non-annualized) and saw its value climb to over 2.2 billion euros.
The quarter also marked significant strategic developments. Gimv divested its majority stake in ALT Technologies to CCL Industries, while portfolio companies advanced their growth plans: Equine Care Group expanded into the US market via Salado Equine Medical Center, Sofatutor acquired SchoolMouv, and BioConnection invested in capacity expansion.
Additionally, the merger of Variass and AME into Metis Group created a stronger electronics manufacturing services platform. Post-quarter, Gimv Anchor acquired a 5 percent stake in Azelis, a global leader in specialty chemicals and food ingredients distribution.
Gimv’s Anchor portfolio highlighted resilience, with Cegeka reporting stable 2025 revenue of 1.3 billion euros despite market caution. The company implemented structural measures to drive long-term value and is gearing up for its next growth phase under new CEO Koen Deryckere. Financially, Gimv secured a 400 million euros revolving credit facility, boosting its investment capacity and maintaining a strong liquidity position of 600 million euros after paying its FY2025 dividend.
While monitoring exposure to rising energy prices and geopolitical risks, Gimv noted limited direct impact so far, though some companies anticipate indirect effects like higher transportation costs. The portfolio’s solid fundamentals, including pricing power and low leverage, provide a buffer against potential challenges. A detailed half-year update is scheduled for 3 September 2026.
